Isocoumarins With Basic Substituents As Serine Proteases Inhibitors, Anticoagulants And Anti-inflammatory Agents by Powers, James C. & Kam, Chih-min
United States Patent [19J 
Powers et al. 
[54] ISOCOUMARINS WITH BASIC 
SUBSTITUENTS AS SERINE PROTEASES 
INHIBITORS, ANTICOAGULANTS AND 
ANTI-INFLAMMATORY AGENTS 
[75] Inventors: James C. Powers, Atlanta; Chih-Min 
Kam, Roswell, both of Ga. 
[73] Assignee: Georgia Tech Research Corporation, 
Atlanta, Ga. 
[21] Appl. No.: 43,647 
[22] Filed: Apr. 28, 1987 
[51] Int. CI.4 ............................................ C07D 311/76 
[52] U.S. CI •.................................... 549/283; 549/285; 
549/288; 548/336; 548/463; 548/525 
[58] Field of Search ....................... 549/283, 285, 288; 
548/336, 463 
[56] References Cited 
U.S. PATENT DOCUMENTS 
2,779,762 1/1957 Robertson et al. ................. 549/285 
OTHER PUBLICATIONS 
Arora et al., CA 104:186277q. 
Reaction of Homophthalic Acid With Phosphorus Pen-
tachloride-V. B. Milevskaya, R. V. Belinskaya, & L. M. 
Yagupol'skii. 
Isocounnarins: Part VI*-3-Alkoxy-4--
Chloroisocoumarins, B. B. Tirookar & R. N. Usgaon-
kar. 
Isocounnarins: Part XV-Nitro-& 7-Amino-Isocouma-
[11] Patent Number: 
[45] Date of Patent: 
4,845,242 
J u_I. 4, 1989 
rins from 4-- Nitrohomophthalic Acid Indira Choksey & 
R. N. Usgaonkar. 
3-Alkoxy-7-Amino-4-chloroisocoumarins: A New 
Class of Suicide Substrates for Serine Protesases J. 
Wade Harper and James C. Powers*. 
Reaction of Serine Proteases with Substituted 3-Alkox-
y-4-Chloroisocoumarins and 3-Alkoxy-7-Amino-4---
Chloroisocoumarins: New Reactive Mechanism-Based 
Inhibitors-I. W. Harper & J.C. Powers. 
Reaction of Serine Proteases with Substituted 
Isocoumarins: Discovery of 3,4-Dichloroisocoumarin a 
New General Mechanism Based Serine Protease In-
hibitor-I. W. Harper & J. C. Powers 
New Mechanism-Based Serine Protease Inhibitors: 
Inhibition of Human Leukocyte Elastase, Procine Pan-
creatic Elastase, Human Leukocyte Cathepsin G, and 
Chymotrypsin by 3-Chloroisocoumarin and 3,3-Di-
chlorophthalide-J. W. Harper, Keiji Hemmi and J. C. 
Powers. · 
The Action of Phosphorous Pentachloride on Homo-
phthalic Acid. 
Primary Examiner-Jane T. Fan 
Attorney, Agent, or Firm-Hurt, Richardson, Garner, 
Todd & Cadenhead 
[57] ABSTRACT 
Substituted isocoumarins, their preparation, their use in 
inhibiting serine proteases with trypsin-like, chymo-
trypsin-like and elastase-like specificity and their roles 
as anticoagulant agents, and anti-inflammatory agents. 
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chains. All of the above enzymes have extensive sec-
ondary specificity and recognize amino acid residues 
removed from the P1 residue. 
It is an object of this invention to discover new prote-
ISOCOUMARINS WITH BASIC SUBSTITUENTS 
AS SERINE PROTEASES INHIBITORS, 
ANTICOAGULANTS AND 
ANTI-INFLAMMATORY AGENTS 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with government support 
under Contract No. HL34035 awarded by the National 
Institutes of Health, National Heart, Lung and Blood 
Institute. The government has certain rights in the in-
vention. 
5 ase inhibitors, especially blood coagulation enzyme 
inhibitors, complement enzyme inhibitors, tryptase in-
hibitors, elastase inhibitors, and plasmin inhibitors. 
These inhibitors are useful for controlling blood coagu-
lation, various inflammatory conditions, and tumor 
10 invasiveness mediated by serine proteases. The inhibi-
tors of this invention would be useful for treating dis-
eases related to blood coagulation enzymes, comple-
ment proteins or plasmin; such as vascular clotting, 
cerebral infarction, coronary infarction, inflammation 
BACKGROUND OF THE INVENTION 
l. Field of the Invention 15 and tumor invasiveness. The inhibitors of this invention 
would also be useful for treating diseases such as pan-
creatitis, emphysema or infantile and adult respiratory 
distress syndrome, which involve the destruction of 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting trypsin-like 
enzymes, selectively inhibiting chymotrypsin-like en-
zymes, selectively inhibiting elastase or for generally 
inhibiting serine proteases of all classes. This invention 20 
also relates to a method of controlling blood coagula-
tion, tumor invasiveness and treating inflammation in 
patients using the novel compounds of the present in-
vention. We have found that substituted isocoumarins 
are potent inhibitors of blood coagulation enzymes, 25 
complement enzymes, tryptases, kallikreins, plasmin 
and elastase, therefore they are useful as anticoagulants, 
anti-inflammatory and anti-tumor agents. 
2. Description of the Related Art 
Serine proteases play critical roles in several physic- 30 
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, and reproduction. 
Serine proteases are not only a physiological necessity, 
but also a potential hazard if they are not controlled. 
Blood coagulation serine proteases are responsible for 35 
vascular clotting, cerebral infarction, and comary in-
farction. Plasmin is involved in tumor invasiveness, 
tissue remodeling, and clot dissociation. Uncontrolled 
proteolysis by other serine proteases such as elastases 
may cause pancreatitis, emphysema, rheumatoid arthri- 40 
tis, inflammation and adult respiratory distress syn-
drome. Accordingly, specific and selective inhibitors of 
these proteases should be potent anticoagulants, anti-in-
flammatory agents and anti-tumor agents useful in the 
treatment of protease-releated diseases (Powers and 45 
Harper, in Proteinase Inhibitors, Barrett and Salvesen, 
eds., Elsevier, 1986, pp 55-152, incorporated herein by 
reference). In vitro proteolysis by trypsin, chymotryp-
sin or the elastase family is a serious problem in the 
production, purification, isolation, transport or storage 50 
of peptides and proteins. 
SUMMARY OF THE INVENTION 
It is an object of this invention to find a novel group 
of specific inhibitors for trypsin, elastase, chymotrypsin 55 
and other serine proteases of similar substrate specificity 
and for serine proteases in general. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 60 
amino acid residue on the carbonyl side of the split bond 
(P1 residue) is Lys or Arg. Elastase and elastase-like 
enzymes, on the other hand, cleave peptide bonds 
where the P1 amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. Chymotrypsin and chymotrypsin- 65 
like enzymes hydrolyze peptide bonds where P1 amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid 
residues which contain aromatic or large alkyl side 
tissue by serine proteases. The inhibitors of this inven-
tion would also be useful for controlling hormone pro-
cessing by serine proteases and for treating diseases 
related to tryptases such as inflammation and skin blis-
tering. 
It is another object of this invention to find a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine pro-
teases of similar specificity and for inhibiting serine 
proteases in general. Such inhibitors could be used to 
identify new proteolytic enzymes encountered in re-
search. They could also be used in research and indus-
trially to prevent undesired proteolysis that occurs dur-
ing the production, isolation, purification, transport and 
storage of valuable peptides and proteins. Such proteo-
lysis often destroys or alters the activity and/or func-
tion of the peptides and proteins. Uses would include 
the addition of the inhibitors to antibodies, enzymes, 
plasma proteins, tissue extracts or other proteins and 
peptides which are widely sold for use in clinical analy-
ses, biomedical research, and for many other reasons. 
For some uses a specific inhibitor would be desirable, 
while in other cases, an inhibitor with general specific-
ity would be preferred. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Substituted isocoumarins have been found to be ex-
cellent inhibitors of several serine proteases including 
bovine thrombin, bovine factor Xa, human factor Xa, 
human factor Xia, human factor Xlla, human plasma 
kallikrein, porcine pancreatic kallikrein, bovine trypsin, 
human plasma plasmin, sheep lung lymph tryptase, 
human complement proteins D, B, C2, human leuko-
cyte elastase, porcine pancreatic elastase, bovine chy-
motrypsin and human leukocyte cathepsin G. These 
compounds inhibit the serine proteases by the reaction 
with the active site serine to form an acyl enzyme, 
which in some cases may further react with another 
active site nucleophile to form an additional covalent 
bond. These structures may be used in vivo to treat 
diseases resulting from abnormal or uncontrolled blood 
coagulation or diseases caused by uncontrolled proteo-
lysis by elastase, chymotrypsin, trypsin and related ser-
ine proteases. These inhibitors may be used in vitro to 
prevent proteolysis which occurs in the process of pro-
duction, isolation, purification, storage or transport of 
peptides and proteins. The novel substituted isocouma-
4,845,242 
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rin and related heterocyclic compounds have the fol-









R is selected from the group consisting of -N-
H-C( NH)-NH2, -C( NH)NH2, C1-6 alkyl 
with an attached amino, and C1.6 alkyl with an 15 
attached isothiureido of the formula 
-S-C( NH2+)NH2, 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1.6 alkyl with an attached phenyl, C1-6 
fluorinated alkyl, C1-6 alkyl with an attached hy- 20 
droxyl, C1.6 alkyl with an attached C1-6 alkoxy, 
C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 alkoxy 
with an attached phenyl, benzyloxy, 4-fluoroben-
zyloxy, -OCH2C6H4R' (2-substituent), 
-OCH2C6li4R' (3-substituent), -OCH2C6li4R' 25 




-OCH2C6H3R2' (3,4-substituents), and 30 
OCH2C6ff 3R2' (3,5-substituents ), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, 
Yis selected from the group consisting ofH, halogen, 35 
trifluoromethyl, methyl, OH, and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
Z is selected from the group consisting of C 1-6 alkoxy 40 
with an attached amino, C1.6 alkoxy with an at-
tached isothiureido, C1-6 alkoxy with an attached 
guanidino, C1-6 alkoxy with an attached amidino, 
C1-6 alkyl with an attached amino, C1-6 alkyl with 
an attached isothiureido, C1-6 alkyl with an at- 45 
tached guanidino, C1-6 alkyl with an attached 
amidino, 
R is selected from the group consisting of H, OH, 
NH2, N02 halogen, C1.6 alkoxy, C1.6 fluorinated 
alkoxy, C1.6 alkyl, C1-6 alkyl with an attached 50 
amino, M-AA-NH-, M-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, praline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 55 
lysine, arginine, histidine, beta-alanine, norleucine, 
norvaline, alpha-aminobutyric and epsilon-
aminocaponic acid, citrulline, hydroxyproline, or-
nithine and sarcosine, 
wherein M represents H, lower alkanoyl having 1 to 60 
6 carbons, carboxyalkanoyl, hydroxyalkanoyl, 
amino-alkanoyl, benzene sulfonyl, tosyl, benzoyl, 
and lower alkyl sulfonyl having 1 to 6 carbons, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 65 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
R is selected from the group cons1stmg of -N-
H-C( NH)-NH2, -C(=NH)NH2, C1-6 alkyl 
with an attached amino, C1-6alkyl with an attached 
isothiureido, 
Z is selected from the group consisting of C1-6 alkoxy 
with an attached amino, C1.6 alkoxy with an at-
tached isothiureido, C1-6 alkoxy with an attached 
guanidino, C1-6 alkoxy with an attached amidino, 
C1-6 alkyl with an attached amino, C1-6 alkyl with 
an attached isothiureido, C1-6 alkyl with an at-
tached guanidino, C1-6 alkyl with an attached 
amidino, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Other substituted isocoumarins have been prepared 
earlier for other purposes (illustrative examples: Davies 
and Poole, J. Chem. Soc., pp 1616-1629 (1928); Milev-
skaya, Belinskaya, and Yagupol'skii, Zhur. Org. Khim. 
9, pp 2145-2149 (1973); Tirodkar and Usgaonkar, Ind. J. 
Chem. 7, pp 1114-1116 ( 1969); Choksey and U sgaonkar, 
Ing. J. Chem. 14B, pp 596-598 (1976), the preceding 
articles are incorporated herein by reference). 
A number of other substituted isocoumarins have 
been prepared recently for inhibition of serine proteases 
(Harper, Hemmi, and Powers, J. Am. Chem. Soc. 105, 
pp 6518-6520 (1983); Harper, Hemmi, and Powers, 
Biochemistry 24, pp 1831-1841 (1985); Harper and 
Powers, J. Am. Chem. Soc. 106, pp 7618-7619 (1984); 
Harper and Powers, Biochemistry 24, 7200-7213 
(1983), the preceding articles are incorporated herein by 
reference; and Powers and Harper, U.S. Pat. No. 
4,596,822, which is also incorporated by reference). 














It has been found that compounds of Formula (I) 
have anticoagulant activity as shown in Table I and 
Table VI by effective inhibitions of the proteolytic 
function of blood coagulation enzymes in Hepes buffer 
and in human plasma. It has also been found that com-
pounds of formula (I) have anti-tumor activity as shown 
in Table I by the effective inhibition of the proteolytic 
function of human plasma plasmin. Compounds of For-
mula (I) are effective in the treatment of organic rejec-
tion as shown in Table II by the effective inhibition of 
the proteolytic function of complement proteins. Com-
pounds of Formula (I) have anti-inflammatory activity 
and are effective in the prevention and inhibition of 
edema and granuloma tissue formation as shown in 
Table IV by the effective inhibition of the proteolytic 
function of human leukocyte elastase. Compounds of 
Formula (I) are effective in the detection, prevention 
and inhibition of adult and infantile respiratory distress 
syndrome (a consequence of acute lung injuries) as 
shown in Table III by the effective inhibition of the 
proteolytic function of sheep lung lymph tryptase. 
Sheep lung lymph tryptase is utilized as a marker of 
4,845,242 
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lung capillary injury, and this is shown in the article by 
Lesser et al., Am. Rev. Respir. Dis. 135, pp 643-650 
(1987), which is incorporated herein by reference. 
Inactivation rates of serine proteases by substituted 
isocoumarins were measured by incubation method. An 5 
aliquot of inhibitor (25 or 50 µl) in Me2SO was added to 
a buffered enzyme solution (0.01-2.3 µM) to initiate the 
inactivation. Aliquots (50 µl) were withdrawn at vari-
ous intervals and the residual enzymatic activity was 
measured. Me2SO concentration in the reaction mixture 10 
was 8-12% (v/v). 0.1 Hepes, O.OlM CaCh, pH 7.5 
buffer was utilized for trypsin and coagulation enzymes. 
O.lM Hepes, 0.5M NaCl, pH 7.5 was utilized for other 
serine proteases. The inhibitor concentrations are 
shown in the Tables I, II, Ill, and IV. Peptide thioesters 15 
or peptide nitroanilides with appropriate sequence were 
used as substrates for various serine proteases. All pep-
tide thioester hydrolysis rates were measured with assay 
mixtures containing 4,4' -dithiodipyridine 
(E324= 19,800M-lcm-1; Grasetti & Murray, Arch. Bio- 20 
chem. Biophys. 119, pp 41-49 (1967)). Peptide 4-
nitroanilide hydrolysis was measured at 410 nm 
(E410=8800M-lcm-l; Erlanger et al., Arch. Biochem. 
Biophys. 95, pp 271-278 (1961)). First order inactiva-
tion rate constant (kobs) were obtained from plots of In 25 
vt/Vo vs time, and the correlation coefficients were 
greater than 0.98. 
Table I shows the inactivation rate constants for sev-
eral trypsin-like serine proteases inhibited by substituted 
isocoumarins. When the isocoumarin structure contains 30 
basic functional groups such as guanidino as R, or ami-
noalkoxy, isothiureidoalkoxy as Z, and Cl as Y, the 
compound is generally a good inhibitor for trypsin and 
blood coagulation enzymes and tryptases. The inactiva-
tion of the enzyme is time dependent, and the kobsl[I] 35 
values are second order rate constants. In most cases, 
inactivation of the enzyme occurs at the inhibitor con-
centration of 5-400 times the enzyme concentration and 
the first order rate constant kobs is obtained. However, 
in some cases, the inactivation wa5 too fast to be mea- 40 
sured under first order rate conditions ([I]> [E]), the 
inactivation rate was measured either in the presence of 
substrate using the progress curve method as described 
by Tian and Tsou, Biochemistry 21, pp 1028-1032 
(1982) or using the same concentration of enzyme and 45 
inhibitor. 7 -guanidino-4-chloro-3-alkoxyisocoumarins 
are essentially stoichiometric inactivators of trypsin, 
thrombin and kallikrein. The inactivation rate of the 
enzyme depends on the substituents R, Z and Y. The 
structure with R groups of guanidino, and Y groups of 50 
Cl is the best inhibitor for trypsin and all the coagula-
tion enzymes tested. The isocoumarins with Y groups of 
Cl and Z groups of isothiureidoalkoxy are potent inhibi-
tors toward trypsin-like enzymes. 7-Guanidino-3-
methoxy-4-chloroisocoumarin is a good inhibitor for 55 
plasmin. 
Table II shows the inactivation of complement prote-
ins D, B, C2 by substituted isocoumarins. 3-Isothi-
ureidoalkoxy-4-chloroisocoumarins inhibit protein B 
and C2, while other serine protease inhibitors such as 60 
4-amidinophenylmethane sulfonyl fluoride (APMSF) 
and 3,4-dichloroisocoumarin do not show any inhibition 
toward these two enzymes. Table III shows the inacti-
vation of sheep lung lymph tryptase by substituted 
isocoumarins. 7-Guanidino-3-alkoxy-4-chloroisocouma- 65 
rins are good inhibitors for the tryptase. Table IV shows 
the inactivation rate constant for porcine pancreatic 
elastase (PPE), human leukocyte elastase (HLE), chy-
motrypsin and cathepsin G inhibited by substituted 
isocoumarins. Although the inactivation by the inhibi-
tors was less efficient toward these four enzymes than 
trypsin-like enzymes, the isocoumarin with R group of 
guanidino, Y group of Cl, and Z-group of ethoxy is a 
good inhibitor for PPE, HLE and cathepsin G. The 
structure with Z-group of 2-phenylethoxy is best at 
inhibiting chymotrypsin. 
The spontaneous hydrolysis rates of these substituted 
isocoumarins in Hepes buffer solution and plasma have 
been measured and summarized in Table V. The 
isocoumarins with H at position 4 are 3-6 times more 
stable than the compounds with Cl at the same position. 
7-Amino-4-chloro-3-(3-isothiureidopropoxy)isocouma-
rin is fairly stable in plasma. 7-Guanidino-4-chloro-3-
alkoxyisocoumarins are hydrolyzed in plasma with half-
lives of 5-8 min. 
Table VI shows the prothrombin time of human 
plasma measured in the presence of various inhibitors. 
7-Guanidino-3-methoxy-4-chloroisocoumarin and 7-
guanidino-3-ethoxy-4-chloroisocournarin can prolong 
the slotting time from 11-14 sec to 168, and >240 sec 
respectively without preincubation of plasma and inhib-
itor. With preincubation, these two compounds still can 
prolong the time to 23 and 80 sec respectively. 
Anticoagulants can prolong the clotting time of 
human plasma and play important roles in the treatment 
of blood coagulation related diseases such as vascular 
clotting, cerebral infarction and coronary infarction 
(Williams et al., Hemotalogy, 3rd ed. McGraw Hill, 
1983 and Ingram et al., Bleeding Disorders, 2nd ed. 
Blackwell Scientific Publications, 1985. These two 
books are incorporated herein by reference). The pres-
ence of certain inhibitors of this invention in the human 
plasma would prolong the prothrornbin time quite ef-
fectively, thus these inhibitors would act as anticoagu-
lants in vivo. Currently, there are a few anticoagulant 
drugs in use clinically, and the inhibitors described in 
this invention can be used as anticoagulants in the treat-
ment of animals. 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of 
emphysema and inflammation (Otterness et al., editor, 
Advances in Inflammation Research, Vol. 11, Raven 
Press 1986, and this article is incorporated herein by 
reference). Thus the .novel inhibitors described here 
should be useful for the treatment of emphysema and 
inflammation. Elastase inhibitors have been used orally, 
by injection or by instillation in the lungs in animal 
studies (Powers, Arn. Rev. Respir. Dis., 127, s54-s58 
(1983); Powers and Bengali, Arn. Rev. Respir. Dis. 134, 
pp 1097-1100 (1986) and these two articles are incorpo-
rated herein by reference). The inhibitors described 
above can be used by any of these routes. 
For treatment of blood coagulation-related diseases, 
tumor invasiveness or inflammation, the compounds of 
Formula (I) may be administered orally, topically or 
parenterally. The term parenteral as used includes sub-
cutaneous injection, intravenous, intramuscular, intra-
sternal injection or infusion techniques. The pharma-
ceutical compositions containing the active ingredient 
may be in a form suitable for oral use, for example as 
tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or grannules, emulsions, hard or 
soft capsules or syrups or elixirs. Dosage levels of the 
order to 0.2 mg to 140 mg per kilogram of body weight 
per day are useful in the treatment of above-indicated 




amount of active ingredient that may be combined with cultures, yeast and purified cloned product in higher 
carrier materials to produce a single dosage form will yield. 
TABLE I 
Inactivation Rates for Inhibition of Tr:r:Qsin-Like Serine Proteases b:t: Substituted Isocoumarins 
k I M-ls-1 
bovine human porcine human human 
bovine factor factor pancreatic plasma human human bovine plasma. 
Inhibitors thrombinb xac Xad kallikreine kallikreii:I factor Xlag factor XIIa" trypsin; plasmini 
3-(3-aminopropoxy)- 3.0 Nik 5.0 30 30 3.0 1,200 36 
isocoumarin 
3-(3-aminopropoxy)- 350 160 860 1,400 380 190 7,600 770 
4-chloroisocoumarin 
3-(2-isothiureidoethoxy )- 4,700 5,600 12,000 280,0001 44,000 39,000 32,000 
4-chloroisocoumarin 
3-(3-isothiureidopropxy)- 1,430 220 19,000 >llD,0001 47,000 27,000 46,000 
4-chloroisocoumarin 
7-amino-3-(3-iso- 630 1,640 60 >110,ooom 1,100 22,000 6,200 410,000" 
thiureidopropoxy)-4-
chloroisocoumarin 
7-guanidino-3-methoxy- 4,900 460 1,900 13,000 1,400 520 3,300 320 
isocoumarin 
7-guanidino-3-methoxy- 290,000" 3,100 11,000 45,000" 240,000" 36,200 20,000 310,000" 3,500 
4-chloroisocoumarin 
7-guanidino-3-ethoxy- 3,700 2,700 16,000 44,000 3,100 1,300 20,000 
isocoumarin 
7-guanidino-3-ethoxy- >55,ooom 26,700 11,000 >200,ooom >500,0001 60,000 22,000 > 110,ooom 
isocoumarin 
7-guanidino-3-(2-phenyl- 5,700 11,000 16,000 62,000 1,200 690 45,000 
ethoxy )isocoumarin 
>270,0001 7-guanidino-3-(2-phenyl- >30,ooom 96,000 11,000 200,ooom 20,000 26,000 > 110,ooom 
ethoxy )-4-chloro-
isocoumarin 
°Conditions were as 0.1 M Hepes, 0.01 M C3.Clz, pH 7.5 and 8-12% Me2SO and 25" C. Rate constants were measured by incubation method unless otherwise noted. An 
aliquot of inhibitor was added to an enzyme solution and aliquots removed with time and assayed for remaining enzymatic activity. First-order rate constants, kobs were 
obtained from the plots of In (v,Jv0) versus time. 
binhibitor concentrations were from 0.3 to 400 µ.M. 
"Inhibitor concentrations were from 0.4 to 310 µM. 
dlnhibitor concentrations were from 5 to 105 µM. 
ernhibitor concentrations were from 0.4 to 300 µM. 
finhibitor concentrations were from 0.3 to 300 µM. 
8Jnhibitor concentrations were from 3 to 330 µ.M. 
~Inhibitor concentrations were from 3 to 330 µM. 
~Inhibitor concentrations were from l to 12 µ.M. 
'Inhibitor concentrations were from 8 to 330 µM. 
kNo inhibition. 
1Inactivation was extremely rapid, and the kob/[I} values were based on the residual enzymatic acitivty at 0.2 min. 
msecond-order rate constant was obtained from same concentration of enzyme and inhibitor. 
ninactivation rate constants were obtained by progress curve method described by Tran and Tsou, Biochemistry 21, 1028-1032 (1982). 
vary depending upon the host treated and th~ particular 
mode of administration. 
TABLE II 
To use the above inhibitors in vitro, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
Inactivation of Complement Proteins by Substituted 
Isocoumarins and APMSF" 
kobsl[I] (M-ls-1) 
Inhibitors ob C2C BC 
APMSF 110 Nid NI 
3,4-dichloroisocoumarin 192 Niii NI 
3-(2-isothiureidoethoxy)- 61 1.5 13 
4-chloroisocoumarin 
3-(3-isothiureidopropoxy)- 145 0.5 0.4 
4-chloroisocoumarin 
or ethanol, and are added to an aqueous solution con- 45 
taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 50 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma proteins and would make purification 55 
of the proteins easier. The inhibitors disclosed here 
would be used in cloning experiments utilizing bacterial 
"Conditions were 0.1 M Hepes, 0.5 M NaCl, pH 7.8, 8-10% Me2SO and at 25° C. 
The inactivation rates were measured by incubation method. 
hinhibitor concentration were from 0.5 to 0.12 mM. 
'"Inhibitor concentration were from 0.3 to 1.25 mM. 
dNo inhibition. 
TABLE III 
The Inactivation Rates of Sheep Lung Lymph Tryptase by Substituted 


























The Inactivation Rates of Sheep Lung Lymph Tryptase by Substituted 


























ll'J'he inactivation rates were measured at 0.1 M Hepes, 0.5 M NaCl, pH 7 .5, and 25a C., the reaction 
mixture contains 8% MeiSO. Enzyme concentraton was 11-17 nM. 
bnie inhibition rate was measured at 0.1 M Hepes, 0.5 M NaCl, pH 7.0, 25° C. 
TABLE IV 
Inactivaton Rates for Inhibition of Serine Proteases b:z'. Substituted Isocoumarinsa 
kQfli{I] (M- 1s- 1} 
Inhibitors PPE6 HLEC Chymotrysind Cathepsin G• 
3-(3-aminopropoxy)isocoumarin 2.3 47 38 2.8 
3-(3-aminopropoxy)-4-chloro- 70 860 580 260 
isocoumarin 
3-(2-isothiureidoethoxy)-4-chloro- 270 220 1,300 110 
isocoumarin 
3-(3-isothiureidopropoxy)-4-chloro- 70 2,000 1,700 83 
isocoumarin 
7-amino-3-(3-isothiureidopropoxy)- 1.0 630 4,400 36 
-4-chloroisocoumarin 
7 -guanidino-3-methoxyisocoumarin 55 320 270 _J 
7-guanidino-3-methoxy-4-chloro- 860 6,400 7,200 11,000 
isocoumarin 
7-guanidino-3-ethoxyisocoumarin 86 1,900 990 _g 
7-guanidino-3-ethoxy-4-chloro 2,300 81,00 37,000 84,00 
isocoumarin 
7-guanidino-3-(2-phenylethoxy )- Nih 0.9 2,600 _i 
isocoumarin 
7-guanidino-3-(2-phenylethoxy)- 5.7 73 38,000 66,000 
4-chloriscoumarin 
alnactivation rates were measured at 0.1 M Hepes, 0.5 NaCl, pH 7.5, 8-12% and 25° C. by incubation 
method. An aliquot of inhibitor was added to a solution of enzyme and aliquots removed with time and 
assayed for remaining activity. 
htnhibitor concentrations were from 0.01 to 0.51 mM. 
"Inhibitor concentrations were from 0.001 to 0.18 mM. 
dlnhibitor concentrations were from 0.004 to 0.33 mM. 
'lnhibitor concentrations were from 0.002 to 0.35 mM. 
linhibition was not time dependent, 81 % inhibition was obtained at 0.49 mM. 
KJ.nhibition was not time dependent, 87% inhibition was .obtained at 47 µ.M. 
hNo inhibition. 




Half-Lives for Spontaneous Hydrolysis of Isocoumarin 
Derivatives in Hepes Buffer" and in Human Plasma 





































"Conditions were 0.1 Hepes, 0.5 M NaCl, pH 7.5 and 9% Mei SO at 25° C. Spontane-
ous hydrolysis rates were measured spectrophotometrically by monitoring the 
decrease in absorbance due to the isocoumarin ring system (wavelength 335-380 






7-guanidino-3-methoxy- 33 55 
4-chloroisocoumarin 




















"The prothrombin time described by Quick et. al., Am. J. Med. Sci. 190, pp 501-511 
(1935) was used to measure the clotting time after adding calcium and tissue factor 
65 ro the plasma or to the plasma with inhibitor. 
The following examples are given to illustrate the 






2-Bromoethyl 2-carboxyphenylacetate was prepared 
from heating 10 g ofhomophthalic acid (S6 mmole) and 
5 
21 g of2-bromoethanol (167 mmole) in 175 ml of ben-
zene with a few drops of cone. sulfuric acid at 90° -110° 
for two hours, yield 64%. TLC shows that it is a pure 10 
compound. The cyclization of 2-bromoethyl 2-carboxy-
phenylacetate with PCls was performed by a previous 
method with modification (Tirodkar, and Usgaonkar, 
Indian. J. Chem. 7, pp 1114-1116 (1969)). l.lS g of 
2-bromoethyl 2-carboxyphenylacetate was heated with 15 
2.1 g of PCls in 90 ml of benzene at 70° C. for 2 hrs. The 
benzene was removed and the residue triturated with 
petroleum ether. The crude product was purified by 
silica gel column chromatography with methylene 
chloride as an eluent to give S60 mg of 3-(bromoethyl)- 20 
4-chloroisocoumarin (yield, 46% ). IR and NMR spectra 
show it was the desired product. 100 mg of 3-
bromomethyl-4-chloroisocoumarin (0.3 mmole) was 
heated with 60 mg of thiourea (0.8 mmole) in S ml of 
THF at 70° C. for 2 days·to give a yellow solid, SO mg 25 
(yield, 40%), m.p. 167°-169° C. (dee); one spot on TLC, 
Rp0.7 (Butanol:acetic acid:water=6:l:S); NMR spec-
trum (d6·DMSO), o 9.1(2b,4H), 7.S-8.1(m,4H), 4.6 (t, 
2H), 3.6 (t, 2H); mass spectrum (FAB+), m/e=299 
(M+-Br). Anal. Cale. for C12H12N203BrtCl1S1: C, 30 
37.96; H, 3.19; N, 7.38. Found: C, 37.81; H, 3.27; N, 7.71. 
EXAMPLE2 
Preparation of 7-Guanidino-3-Methoxyisocoumarin 
Methyl 2-carboxy-4-nitrophenyl acetate was pre- 35 
pared from 2-carboxy-4-nitrophenylacetate and metha-
nol by the procedure described above. Hydrogenation 
of this nitro compound gives methyl 4-amino-2-carbox-
yphenylacetate (yield 90% ). The guanidination of the 
amino compound with 3,S-dimethylpyrazole-1-carbox- 40 
amidine nitrate (ADMP) was performed by a standard 
method described previously (Tsunematsu & Makismi, 
J. Biochem. 88, pp 1773-1783, (1980)). 2.2 g of amino 
compound (10 minole), 1.9 g of triethylamine (19 
mmole) and 3.0 g of ADMP (lS mmole) was heated in 45 
20 ml ofTHF and refluxed for 18 hrs. The white precip-
itate was filtered and washed with cold methanol to 
give 1.S g of methyl 2-carboxy-4-guaniqinophenylace-
tate, (yield 46% ). One spot on TLC, Rp0.6 (Butanol:a-
cetic acid:pyridine:water=4:1:1:2), it shows an orange 50 
color when sprayed with Sakaguchi reagent. NMR 
spectrum (CF3COOH), o 8.4, 7.7 (b, 4H), 6.6 (b, 4H) 4.4 
(s, 2H), 4.1 (s, 3H). Anal. Cale. for C11H13N304.!ff20: 
C, S0.77; H, S.42; N, 16.lS. Found: C, Sl.03; H, S.38; N, 
16.19. 0.9 g of methyl 2-carboxy-4-guanidinophenylace- 55 
tate (3 mmole) was heated with 1.S g of PCls (7.2 
mmole) at 70°-80° C. for 2 hrs, white solid precipitated 
out during the heating. The solid was filtered off and 
purified by silica gel column chromatography with 
methylene chloride and methanol (S:l) as an eluent to 60 
give 0.S g of 7-guanidino-3-methoxyisocoumarin (yield 
S9%). One spot on TLC, Rp0.7 (Butanol:acetic acid: 
pyridine:water=4:1:1:2); m.p. 185°-186° C. (dee);, 
NMR spectrum (d6-DMSO): o 7.9, 7.6 (b, 3H), 7.7 (b, 
4H), 6.1 (s, lH), 3.9 (s, 3H); mass spectrum (FAB+), 65 
m/e=234 (M+-Cl). Anal. Cale. for C11H12N303Cld 
H10: C, 47.40; H, 4.67; N, lS.08; Cl, 12.7S. Found: C, 




0.27 g of 7-guanidino-3-methoxyisocoumarin (1 
mmole) was chlorinated with O. lS g ofN-chlorosuccini-
mide (1.1 mmole) in S ml DMF at r.t. overnight. The 
reaction mixture was evaporated to dryness, and puri-
fied by silica gel column chromatography which is 
eluted with methylene chloride and methanol (S:l) to 
give 0.1 g of 7-guanidino-3-methoxy-4-chloroisocouma-
rin (yield 34%). One spot on TLC, Rp0.7S (Butanol:a-
cetic acid:pyridine:water=4:1:1:2); NMR spectrum is 
similar to 7-guanidino-3-methoxyisocoumarin except no 
peak at 6.1 ppm; mass spectrum (FAB+), m/e=268 
(M+-Cl). Anal. Cale. for C11H11N303C}z.!H20: C, 
42.17; H, 3.83; N, 13.41; Cl, 22.68. Found: C, 42.65; H, 
3.72; N, 13,28; Cl, 22.32. 
EXAMPLE4 
Preparation of 3-(3-Aminopropoxy)isocoumarin 
Hydrochloride 
Homophthalic acid (18 g, 0.1 mole) and 3-(benzylox-
ycarbonylamino)-1-propanol (41 g, 0.2 mole) were 
heated in lSO ml of benzene at 120°-130° C. for 2 hrs in 
the presence of a few drops of cone. H1S04. Benzene 
was evaporated, and 200 ml of ethylacetate was added. 
The organic solution was washed with 4% NaHC03 
twice (150 mlX2). The aqueous layer which contained 
the monoester salt was acidified with SN HCl and ex-
tracted with ethylacetate. 33 g of 3-(benzyloxycar-
bonylamino )propyl 2-carboxyphenylacetate (yield, 
89%) was obtained after the solvent was evaporated. 
Hydrogenation of this monoester (1.86 g, S mmole) was 
performed in methanol containing 0.3 ml of acetic acid 
and 10% palladium on carbon to give 1 g of 3-amino-
propyl 2-carboxphenylacetate.HAc (yield, 67%). This 
compound was identified by its NMR spectrum and 
TLC (Butanol:acetic acid:pyridine:water=4:1:1:2). 2 g 
of 3-aminopropyl 2-carboxyphenylacetate.HAc (3 
mmole) was heated with 1.6 g of PCls (7.S mmole) in SO 
ml of anhydrous THF at 70° -80° for 2 hrs, a white 
precipitat~ formed. This white solid was purified by 
column chromatography (methylene chloride:me-
thanol = S: l) and crystalline from MeOH-ether to give 
0.2 g of 3-(3-aminopropoxy)isocoumarin.HCl (yield, 
26%), m.p. 173°-174° C.; mass spectrum, m/e=220 
(M+-Cl). Anal. Cale. for C12H1~103Cl1: C, S6.37; H, 
S.S2; N, S.48; Cl, 13.87. Found: C, S6.1S; H, S.49; N, 





0.13 g of 3-(3-aminoproxy)isocoumarin hydrochlo-
ride (O.S mmole) was chlorinated with 0.07 g of N-
chlorosuccinimide (0.S mmole) in S ml of DMF at r.t. 
overnight. The reaction mixture was purified by silica 
gel column chromatography (methylene chloride:me-
thanol= S: l) and crystallized from MeOH-ether to give 
0.09 g of 3-(3-aminopropoxy)-4-chloro-isocoumarin 
hydrochloride (yield, 60% ). NMR spectrum of this 
compound is similar to 3-(3-aminopropoxy)isocoumarin 
without the peak at o 6.2 ppm; m.p. 160°-163° C.; mass 
spectrum, m/e=2S4 (M+-Cl). Anal. Cale. for 
4,845,242 
14 13 
C12H13N103Clz.!H20: C, 48.88; H, 4.61; N, 4.75; Cl, 






This compound was synthesized by the same proce-
dure as 3-(3-isothiureidopropoxy)-4-chloroisocoumarin .. 10 
3-Bromopropyl 2-carboxy-4-nitrophenylacetate was 
prepared from 2-carboxy-4-nitrophenylacetate and 3-
bromopropanol, yield 60%. Cyclization of the monoes-
ter with PCls gives 3-bromopropoxy-4-chloro-7-
nitroisocoumarin (yield, 60%). Hyrogenation of the 15 
nitro. compound (0.36 g) in methanol gives 0.12 g of 
7-amino-3-bromopropoxy-4-chloroisocoumarin, which 
is purified by silica gel column chromatography with 
methylene chloride as an eluent (yield, 36%). This 
aminoisocoumarin reacts with thiourea in THF to give 20 
the final product, which can be crystallized from 
MeOH-ether (yield, 40%), mp 160°-162° C. (dee); one 
spot on TLC, Rj=0.6 (Butanol:acetic acid:pyridine 
water=4:1:1:2); mass spectrum (FAB+), m/e=328 
(M+-Br). Anal. Cale. for C13H15N303Cl1Br1S1: C, 25 
38.20; H, 3.70; N, 10.28; Cl, 8.67. Found: C, 38.15; H, 
3.73; N, 10.25; Cl, 8.63. 
What is claimed is: 






or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of -N- 40 
H-C( NH)-NH2, -C( NH)NH2, amino-Ct-6 
alkyl, and isothiureido-C1.6 alkyl, 
Z is selected from the group consisting of H, halogen, 
Ct-6 alkyl, Ct-6 alkyl with a phenyl group attached 
to the alkyl group, C1-6 fluorinated alkyl, Ct-6 alkyl 45 
with an hydroxyl group attached to . the alkyl 
group, C1-6alkyl with a C1-6alkoxy group attached 
to the alkyl group, Ct-6 alkoxy, Ct-6 fluorinated 
alkoxy, Ct-6 alkoxy with a phenyl group attached 
to the alkoxy group, benzyloxy group wherein the 50 
phenyl group is unsubstituted or substituted by one 
or two substituents selected from halogen, trifluo-
romethyl, N02, cyano, methyl, methoxy, acetyl, 
carbonyl, OH, and amino, and 55 Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
60 
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or a pharmaceutically acceptable salt thereof, wherein 
Z is selected from the group consisting of C1-6 alkoxy 
with an amino group attached to the alkoxy group, 
Ct-6 alkoxy with an isothiureido group attached to 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, C1-6 alkyl with an amino group attached to 
the alkyl group, Ct-6 alkyl with an isothiureido 
group attached to the alkyl group, C 1-6 alkyl with a 
guanidino group attached to the alkyl group, Ct-6 
alkyl with an amidino group attached to the alkyl 
group, 
R is selected from the group consisting of H, OH, 
NH2, N02, halogen, C1-6 alkoxy, C1-6 fluorinated 
alkoxy, Ct-6 alkyl, amino-Ct-6 alkyl, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
3. A compound of the formula: 
0 
RW" I o 
.# .# z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of -N-
H-C(=NH)-NH2, -CC NH)NH2, amino-C1-6 
alkyl, and isothiureido-Ct-6 alkyl, 
Z is selected from the group consisting of C1-6 alkoxy 
with an amino group attached to the alkoxy group, 
Ct-6 alkoxy with an isothiureido group attached to 
the alkoxy group, Ct-6 alkoxy with a guanidino 
group attached to the alkoxy group, Ct-6 alkoxy 
with an amidino group attached to the alkoxy 
group, Ct-6 alkyl with an amino group attached to 
the alkyl group, Ct-6 alkyl with an isothiureido 
group attached to the alkyl group, C1-6alkyl with a 
guanidino group attached to the alkyl group, C1-6 
alkyl with an amidino group attached to the alkyl 
group, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
* * * * * 
